Revenue Insights: BioCryst Pharmaceuticals, Inc. and MiMedx Group, Inc. Performance Compared

Biotech Revenue Growth: BioCryst vs. MiMedx

__timestampBioCryst Pharmaceuticals, Inc.MiMedx Group, Inc.
Wednesday, January 1, 201413608000118223000
Thursday, January 1, 201548257000187296000
Friday, January 1, 201626353000245015000
Sunday, January 1, 201725186000321139000
Monday, January 1, 201820653000359111000
Tuesday, January 1, 201948835000299255000
Wednesday, January 1, 202017812000248234000
Friday, January 1, 2021157170000258615000
Saturday, January 1, 2022270827000267841000
Sunday, January 1, 2023331412000321477000
Loading chart...

In pursuit of knowledge

Revenue Growth: A Tale of Two Biotech Companies

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success. BioCryst Pharmaceuticals, Inc. and MiMedx Group, Inc. have shown intriguing revenue trajectories from 2014 to 2023. BioCryst Pharmaceuticals started with a modest revenue of $13.6 million in 2014, but by 2023, it had surged to over $331 million, marking an impressive growth of over 2300%. Meanwhile, MiMedx Group, Inc. began with a stronger revenue base of $118 million in 2014, reaching $321 million by 2023, reflecting a steady growth of approximately 172%.

This decade-long journey highlights the resilience and strategic advancements of these companies in the competitive biotech sector. While BioCryst's revenue growth was more volatile, MiMedx maintained a more consistent upward trend, showcasing different paths to success in the industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025